Aura Biosciences reports 2026 shareholder vote results

Aura Biosciences, Inc. reported the results of its 2026 Annual Meeting of Stockholders.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Aura Biosciences, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Common stock entitled to vote totaled 64,199,778 shares, with 52,784,744 shares present or represented by proxy.

Stockholders elected David Johnson and Teresa Marie Bitetti as Class II directors to serve until the 2029 Annual Meeting, with Johnson receiving 34,542,193 votes for and Bitetti receiving 40,526,332 votes for. Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 52,752,601 votes for, 17,348 against and 14,795 abstentions, and no broker non-votes.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares entitled to vote: 64,199,778 shares Shares present or by proxy: 52,784,744 shares Votes for David Johnson: 34,542,193 votes +5 more

8 metrics

Shares entitled to vote 64,199,778 shares Common stock entitled to vote at 2026 Annual Meeting

Shares present or by proxy 52,784,744 shares Common stock present or represented at 2026 Annual Meeting

Votes for David Johnson 34,542,193 votes Election as Class II director at 2026 Annual Meeting

Votes for Teresa Marie Bitetti 40,526,332 votes Election as Class II director at 2026 Annual Meeting

Broker non-votes on director election 11,614,254 votes Broker non-votes for each director nominee

Votes for auditor ratification 52,752,601 votes Ratification of Ernst & Young LLP for fiscal year ending Dec. 31, 2026

Votes against auditor ratification 17,348 votes Opposing votes on Ernst & Young LLP ratification

Abstentions on auditor ratification 14,795 votes Abstaining votes on Ernst & Young LLP ratification

Key Terms

Annual Meeting of Stockholders, broker non-votes, independent registered public accounting firm, definitive proxy statement, +1 more

5 terms

Annual Meeting of Stockholders financial

"On June 11, 2026, Aura Biosciences, Inc. held its 2026 Annual Meeting of Stockholders"

broker non-votes financial

"Broker Non-Votes ... 11,614,254 ... There were zero broker non-votes regarding this proposal"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

independent registered public accounting firm financial

"ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

definitive proxy statement regulatory

"each such proposal described in the Company’s definitive proxy statement for the Annual Meeting"

A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.

Class II directors financial

"elected the two (2) director nominees below to the Company’s Board of Directors as Class II directors"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aura Biosciences (AURA) shareholders vote on at the 2026 Annual Meeting?

Shareholders voted on electing two Class II directors and ratifying Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, based on proposals described in the company’s April 20, 2026 definitive proxy statement.

Were Aura Biosciences (AURA) director nominees elected at the 2026 Annual Meeting?

Yes, both Class II director nominees, David Johnson and Teresa Marie Bitetti, were elected. Johnson received 34,542,193 votes for, while Bitetti received 40,526,332 votes for, and each will serve until the 2029 Annual Meeting of Stockholders, subject to earlier departure events.

How many Aura Biosciences (AURA) shares were entitled to vote at the 2026 meeting?

A total of 64,199,778 shares of Aura Biosciences common stock were entitled to vote. Of these, 52,784,744 shares were present or represented by valid proxy at the meeting, providing the quorum required to conduct official stockholder business and approve the proposals.

Did Aura Biosciences (AURA) shareholders ratify Ernst & Young LLP as auditor?

Yes, shareholders ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 52,752,601 votes for, 17,348 against and 14,795 abstentions. There were no broker non-votes reported on this proposal.

What were the broker non-votes at Aura Biosciences’ 2026 Annual Meeting?

For Proposal 1, electing directors, broker non-votes totaled 11,614,254 for each nominee. For Proposal 2, ratifying Ernst & Young LLP as auditor, there were zero broker non-votes, meaning intermediary brokers cast discretionary votes where permitted.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/11/2026 - 04:31 PM EDT

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

      Date of Report (Date of earliest event reported): June 11, 2026

     

Aura Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-40971	32-0271970
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

80 Guest Street
Boston, Massachusetts		02135
(Address of Principal Executive Offices)		(Zip Code)

      Registrant’s Telephone Number, Including Area Code: 617 500-8864

     

      Not Applicable

     

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.00001 par value per share	AURA	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 11, 2026, Aura Biosciences, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The proposals set forth below were submitted to the stockholders at the Annual Meeting, with each such proposal described in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 20, 2026.

The number of shares of the Company’s common stock, par value $0.00001 per share (“Common Stock”), entitled to vote at the Annual Meeting was 64,199,778. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 52,784,744. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each proposal voted upon at the Annual Meeting are set forth below.

Proposal 1 - Election of Directors

The Company’s stockholders elected the two (2) director nominees below to the Company’s Board of Directors as Class II directors to serve until the 2029 Annual Meeting of Stockholders of the Company and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal.


Director Nominee	Votes For		Votes Withheld		Broker Non-Votes
David Johnson		34,542,193		6,628,297		11,614,254
Teresa Marie Bitetti		40,526,332		644,158		11,614,254

Proposal 2 - Ratification of Appointment of Independent Registered Accounting Firm

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026.


Votes For	Votes Against	Abstentions
52,752,601	17,348	14,795

There were zero broker non-votes regarding this proposal.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			Aura Biosciences, Inc.

Date:	June 11, 2026	By:	/s/ Natalie Holles
			Natalie Holles Chief Executive Officer and President (Principal Executive Officer)

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document